Bank of Montreal vs Nuwellis Inc — how do they compare? Bank of Montreal trades at $183.1 (market cap $125.53B), while Nuwellis Inc trades at $3.05 (market cap $1.17M). The key difference: Bank of Montreal is far larger — about 107290.6× Nuwellis Inc's market cap, and Bank of Montreal pays a 2.74% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals.
| BMO | NUWE | |
|---|---|---|
Market Cap | $125.53B | $1.17M |
Sector | Financials | Technology |
52-Week High | $180.86 | $558.26 |
52-Week Low | $110.44 | $2.80 |
Dividend Yield | 2.74% | — |
Enterprise Value | — | -$636.97K |
Signals from Pluang's Aura AI — not financial advice
BMO trades at $178.69, down 0.15% today, with a bullish technical signal supported by moving averages and key resistance at $180. The company reported strong Q1 2026 earnings of $2.68 per share, beating estimates, and maintains a solid net income margin of 25.92%. Recent acquisitions and dividend increases highlight strategic growth, while analyst sentiment is balanced with 44% buy ratings.
Outlook remains positive driven by consistent earnings beats and expansion in metals & mining banking. Risks include valuation above historical norms with a P/E of 19.48 and exposure to interest rate sensitivity. The stock offers a compelling dividend yield but faces macroeconomic headwinds that could pressure future performance.
NUWE trades at $2.80, down 7.89% in the last session, with a bearish technical outlook. The company reported a net loss of $17.52M in 2025 despite $8.27M revenue, reflecting negative profit margins and cash flow challenges. Recent news highlights expansion in pediatric care and a $6M public offering closed in June 2026, alongside a CEO transition to Mike McCormick effective June 30, 2026.
Outlook remains high-risk due to persistent losses and cash burn, though analyst consensus is split evenly between Buy and Hold. Key risks include execution in revenue growth and reliance on financing. Upside depends on successful commercialization of Aquadex therapy and FDA label expansion for pediatric patients.
Trailing returns across standard periods
Latest headlines on both assets
Bank of Montreal is a diversified financial-services provider based in North America, operating four business segments: Canadian personal and commercial banking, U.S. P&C banking, wealth management, and capital markets. The bank's operations are primarily in Canada, with a material portion also in the U.S.
Read more on BMO →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →